Immunic advances Phase 3 MS program, eyes topline data by year-end

Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Wednesday it remains on track to deliver top-line phase 3 data for its lead multiple sclerosis drug candidate, vidofludimus calcium, by the end of 2026, as the company strengthens its leadership team and bolsters its balance sheet with a recently completed $200 million private financing. Along with the release of its first quarter financial results, the biotechnology company said it continues to advance its twin phase 3 ENSURE-1 and ENSURE-2 trials evaluating vidofludimus calcium in relapsing multiple sclerosis (RMS).